Axogen Inc Total Liabilities
Axogen Inc total liabilities. Based on the latest financial reports, Axogen Inc (AXGN) has total liabilities worth $44.68 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Axogen Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Axogen Inc (1986–2025)
Total liabilities of Axogen Inc from 1986 to 2025. This chart illustrates how Axogen Inc's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Axogen Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Axogen Inc Competitors by Total Liabilities
The table below lists competitors of Axogen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ:NAMS
|
USA | $58.36 Million |
|
Navios Maritime Partners LP Unit
NYSE:NMM
|
USA | $2.57 Billion |
|
Jizhong Energy Resources Co Ltd
SHE:000937
|
China | CN¥33.64 Billion |
|
China Leadshine Technology Co Ltd
SHE:002979
|
China | CN¥1.27 Billion |
|
Liaoning Cheng Da Co Ltd
SHG:600739
|
China | CN¥17.32 Billion |
|
Hubei Zhenhua Chemical Co Ltd
SHG:603067
|
China | CN¥1.83 Billion |
|
Northwest Bancshares Inc
NASDAQ:NWBI
|
USA | $15.29 Billion |
|
Hufvudstaden AB (publ)
ST:HUFV-A
|
Sweden | Skr21.47 Billion |
Liability Composition Analysis (1986–2025)
This chart breaks down Axogen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Axogen Inc assets under control.
Liquidity & Leverage Metrics
Axogen Inc Total Liabilities Ratios Explained
Axogen Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Axogen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Axogen Inc (1986–2025)
The table below shows the annual total liabilities of Axogen Inc from 1986 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $92.84 Million | -6.99% |
| 2024-12-31 | $99.82 Million | -1.33% |
| 2023-12-31 | $101.16 Million | +7.18% |
| 2022-12-31 | $94.39 Million | -1.14% |
| 2021-12-31 | $95.47 Million | +22.04% |
| 2020-12-31 | $78.23 Million | +247.85% |
| 2019-12-31 | $22.49 Million | +70.50% |
| 2018-12-31 | $13.19 Million | -60.85% |
| 2017-12-31 | $33.69 Million | +7.17% |
| 2016-12-31 | $31.44 Million | +7.12% |
| 2015-12-31 | $29.35 Million | +6.16% |
| 2014-12-31 | $27.65 Million | +0.36% |
| 2013-12-31 | $27.55 Million | +19.46% |
| 2012-12-31 | $23.06 Million | +258.99% |
| 2011-12-31 | $6.42 Million | +5517.51% |
| 2010-12-31 | $114.35K | -98.01% |
| 2009-12-31 | $5.75 Million | +2623.10% |
| 2008-12-31 | $211.06K | +4.91% |
| 2007-12-31 | $201.17K | -7.66% |
| 2006-12-31 | $217.87K | +35.44% |
| 2005-12-31 | $160.86K | -69.13% |
| 2004-12-31 | $521.05K | -81.68% |
| 2003-12-31 | $2.84 Million | -10.65% |
| 2002-12-31 | $3.18 Million | +13.29% |
| 2001-12-31 | $2.81 Million | -25.16% |
| 2000-12-31 | $3.75 Million | +39.06% |
| 1999-12-31 | $2.70 Million | +22.73% |
| 1998-12-31 | $2.20 Million | -26.67% |
| 1997-12-31 | $3.00 Million | +114.29% |
| 1996-12-31 | $1.40 Million | -6.67% |
| 1995-12-31 | $1.50 Million | 0.00% |
| 1994-12-31 | $1.50 Million | -11.76% |
| 1993-12-31 | $1.70 Million | +142.86% |
| 1992-12-31 | $700.00K | 0.00% |
| 1991-12-31 | $700.00K | 0.00% |
| 1990-12-31 | $700.00K | -53.33% |
| 1989-12-31 | $1.50 Million | -97.09% |
| 1988-12-31 | $51.60 Million | +4590.91% |
| 1987-12-31 | $1.10 Million | -15.38% |
| 1986-12-31 | $1.30 Million | -- |
About Axogen Inc
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed periphera… Read more